Fig. 5From: Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivoOrally administered DFX markedly inhibited the growth of pancreatic cancer xenografts in nude mice. a DFX (160 and 200Â mg/kg orally, given by gavage every second day, for a total of three treatments per week for 21Â days) significantly inhibited the growth of human pancreatic cancer BxPC-3 xenografts in vivo. b The removed tumors were measured and processed for immunohistochemistry and genetic analyses. c The removed tumors from mice treated with 160 and 200Â mg/kg oral DFX weighed significantly less than the control tumors. d The average weight of mice in each treatment group during the course of treatmentBack to article page